SynthesisGastrointestinal endoscopy2022
Wide-area transepithelial sampling for dysplasia detection in Barrett's esophagus: a systematic review and meta-analysis.
Synthesis in Gastrointestinal endoscopy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Guideline
- Review Article: Advances in the Diagnosis of Dysplasia in Barrett's Oesophagus.Alimentary pharmacology & therapeutics · 2026Review
- A Practical Guide to Incorporating Novel Barrett's Screening/Surveillance Tools into Clinical Practice.Current gastroenterology reports · 2026Review
- Article
- Improving esophageal cancer screening across the globe: Translating knowledge into action.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Review
- Latest Advances in Endoscopic Detection of Oesophageal and Gastric Neoplasia.Diagnostics (Basel, Switzerland) · 2024Review
- Improving clinical outcomes of Barrett's esophagus with high dose proton pump inhibitors and cryoablation.Annals of medicine · 2023Article
- Categorizing Risks within Barrett's Esophagus To Guide Surveillance and Interception; Suggesting a New Framework.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- Surveillance in Barrett's Esophagus: Challenges, Progress, and Possibilities.Gastroenterology · 2023Article
- Barrett's Esophagus: An Updated Review.Diagnostics (Basel, Switzerland) · 2023Review
- Today's Mistakes and Tomorrow's Wisdom in Development and Use of Biomarkers for Barrett's Esophagus.Visceral medicine · 2022Review
- Management of nondysplastic Barrett's esophagus: When to survey? When to ablate?Therapeutic advances in chronic disease · 2022Review
- Retrospective, observational, cross-sectional study of detection of recurrent Barrett's esophagus and dysplasia in post-ablation patients with adjunctive use of wide-area transepithelial sample (WATS-3D).Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsSeattle protocol forceps biopsy sampling (FB) is currently recommended for surveillance in Barrett's esophagus (BE) but limited by sampling error and lack of compliance. Wide-area transepithelial sampling with 3-dimensional analysis (WATS3D; CDx Diagnostics, Suffern, NY, USA) is reported to increase BE dysplasia detection. We assessed the incremental yield and clinical significance of WATS3D for dysplasia detection over FB in a systematic review and meta-analysis.
methodsWe queried major scientific databases for studies using WATS3D and FB from 2000 to 2020. The primary outcome was the incremental yield of WATS3D-detected dysplasia (defined as a composite of indefinite for dysplasia, low- and high-grade dysplasia [HGD] and esophageal adenocarcinoma [EAC]) over FB. Secondary outcomes were incremental yields of HGD/EAC and rate of reconfirmation of WATS3D dysplasia on subsequent FB.
resultsMeta-analysis of 7 eligible studies demonstrated that FB diagnosed dysplasia in 15.9% of cases, whereas the incremental yield with WATS3D was 7.2% (95% confidence interval, 3.9%-11.5%; I
conclusionsWATS3D increases dysplasia detection; however, the clinical significance of this increased dysplasia detection remains uncertain. Data from endoscopic follow-up to ascertain FB histology in patients with dysplasia based solely on WATS3D are needed to determine the optimal clinical application and significance of WATS3D-only dysplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.